June 2017
Price: £95 PLUS VAT
Format: DOWNLOADABLE PDF
This seminar provided the opportunity to discuss the future of biosimilar medicines in the UK.
Delegates assessed the challenges for embedding use in service delivery following the publication of NHS England’s ‘What is a biosimilar medicine?’ guide, the impact of increased competition between originator and biosimilar manufacturers and the next steps for regulation and pharmacovigilance.
Sessions focused on the implications of the UK vote to leave the European Union on access to biosimilars, key issues for clinicians around switching from originator to biosimilar - and the next steps for patient engagement, education and involvement.
